Has Matthew Milowsky, MD received payments from drug or device companies?

Yes. Drug and device makers reported $79 in general payments to Matthew Milowsky, MD across 1 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Milowsky, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Milowsky, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Milowsky, MD

Medical Oncology · New York, NYNPI 1174618987

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, E.r. Squibb & Sons, L.L.C.. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.

$79in general payments, 2019–2025

Across 1 payment — averaging $79.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$79

$4,404,673in research payments, 2019–2025

Across 451 payments — averaging $9766.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$1.7M
Seagen Inc.$1.4M
E.r. Squibb & Sons, L.L.C.$374K
Pfizer$227K
Incyte Corporation$187K
Eli Lilly$163K
plus $367K from 4 others

What the payments were for

Food & beverage$79100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	1	$79

How this compares

$79 in reported general payments places this provider in the 15th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$41,119

Medicare patients

139

Services billed

612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	59	$799,417
WeliregBelzutifan	14	$378,030
InlytaAxitinib	21	$350,925
NubeqaDarolutamide	39	$331,200
CabometyxCabozantinib S-Malate	12	$282,088
LenvimaLenvatinib Mesylate	11	$235,962
OrgovyxRelugolix	68	$171,482
Abiraterone Acetate	46	$44,289
Everolimus	11	$37,372
Prednisone	68	$350
Prochlorperazine Maleate	11	$164
Tamsulosin Hcl	13	$154
Amlodipine Besylate	18	$67

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →